Steroid implant for macular oedema

Ozurdex is an intravitreal implant containing 700 micograms of dexamethasone. It is indicated for the treatment of macular oedema following either branch retinal vein occlusion or central retinal vein occlusion. Treatment must be administered by an ophthalmologist.

Researchers tested Ozurdex in two double-blind, randomised trials in a total of 1267 patients. At 90 days after a single injection, the proportion of patients who had responded was significantly greater in the Ozurdex group than in the sham treatment group (21.8% vs 13.1%, p<0.001). Response was defined as an improvement of 15 letters or more in best corrected visual acuity.

Corticosteroids such as dexamethasone suppress the production of vascular endothelial growth factor, a cytokine that is involved in the development of macular oedema.

View Ozurdex drug record

Further information: Allergan

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more